In this sense, it should be highlighted that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a cell receptor for viral entry, whereas ACE is the target for certain therapeutic treatments for hypertension that could prevent vasoconstriction and disease conditions in Raynaud’s phenomenon. This evidence concerns the gene ACE and Hypertension.